Global Ganja Report

Raphael Mechoulam, the ground-breaking cannabis researcher who first isolated and identified THC in 1964, died in Israel at the age of 92. His passing was announced March 10 by Jerusalem's Hebrew University, where Mechoulam co-founded the Multidisciplinary Center for Cannabinoid Research in 2017.

Despite a heretofore uninspiring record, Biden is poised to complete a trifecta of long-sought reforms of federal cannabis law: giving the industry access to financial services, expungement of convictions for possession, and allowing medical research.

The legalization of hemp-derived cannabinoids by the 2018 Farm Bill has left a yawning regulatory gap that is being avidly exploited by purveyors of high-potency edibles and sketchy vape products.


That's the contention of a report just issued by the leading California cannabis trade group, warning that the law inadvertently opened a "Pandora's box" that poses threats to public health.

Irradiated cannabis? Yes, it’s a reality. While it may sound scary, industry tells us not to worry. Consumer advocacy groups, however, are raising concerns.

The cannabis industry is globalizing fast, which means changes for mainstays of commercial production in Europe and North America, and new players coming on line from regions such as the Middle East, Southeast Asia and Central America. Here’s a brief overview of a few entries from these categories.

The National Football League has awarded a $1 million research grant to study the impacts of cannabinoids on pain management and neuroprotection in football players. The move represents a breakthrough given the NFL's longstanding zero-tolerance stance on cannabis use.

With political and legal space opening for cannabis in state after state, a backlash is manifesting in the idea of caps on the potency—whether of bud, extracts or edibles. Voices from the industry and activist community see this as a throwback to the days of Reefer Madness.

California has finally taken a step to resolve the ambiguities and inconsistencies in the regulation of hemp-derived CBD — a move that could see the state setting a de facto national standard in light of continued inaction by the US Food & Drug Administration.